Oracort e инструкция на русском мазь

An indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.

4% Xylocaine-MPF (Lidocaine HCl (Oracort-E In Orapaste)) Sterile Solution is indicated for the production of topical anesthesia of the mucous membranes of the respiratory tract or the genito-urinary tract. It may be injected transtracheally to anesthetize the larynx and trachea, and it may be administered by retrobulbar injection to provide anesthesia for ophthalmic surgery.

An indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.

Intramuscular

Where oral therapy is not feasible, injectable corticosteroid therapy, including Triamcinolone acetonide (Oracort-E In Orapaste) injectable suspension is indicated for intramuscular use as follows:

Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions.

Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome).

Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.

Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis.

Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia.

Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy.

Neoplastic diseases: For the palliative management of leukemias and lymphomas.

Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy.

Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids.

Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus.

Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis.

Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis and systemic lupus erythematosus.

Intra-Articular

The intra-articular or soft tissue administration of Triamcinolone acetonide (Oracort-E In Orapaste) injectable suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis.

Lidocaine is a local anesthetic (numbing medication). It works by blocking nerve signals in your body.

Lidocaine injection is used to numb an area of your body to help reduce pain or discomfort caused by invasive medical procedures such as surgery, needle punctures, or insertion of a catheter or breathing tube.

Lidocaine injection is also given in an epidural (spinal block) to reduce the discomfort of contractions during labor.

Lidocaine injection is sometimes used to treat irregular heart rhythms that may signal a possible heart attack.

Lidocaine injection may also be used for other purposes not listed in this medication guide.

Temporarily relieving symptoms associated with inflammation, ulcers, and lesions in the mouth caused by injury to the skin. It may also be used for other conditions as determined by your doctor.

Triamcinolone acetonide (Oracort-E In Orapaste) is a topical adrenocortical steroid. It works by reducing skin inflammation (redness, swelling, itching, and irritation) in a way that is not clearly understood.

When 4% Xylocaine-MPF Sterile Solution is used concomitantly with other products containing lidocaine, the total dose contributed by all formulations must be kept in mind.

The dosage varies and depends upon the area to be anesthetized, vascularity of the tissues, individual tolerance and the technique of anesthesia. The lowest dosage needed to provide effective anesthesia should be administered. Dosages should be reduced for children and for elderly and debilitated patients.

Although the incidence of adverse effects with 4% Xylocaine-MPF Sterile Solution is quite low, caution should be exercised, particularly when employing large volumes and concentrations of 4% Xylocaine-MPF Sterile Solution since the incidence of adverse effects is directly proportional to the total dose of local anesthetic agent administered. For specific techniques and procedures refer to standard textbooks.

There have been adverse event reports of chondrolysis in patients receiving intra-articular infusions of local anesthetics following arthroscopic and other surgical procedures. 4% Xylocaine-MPF is not approved for this use.

The dosages below are for normal, healthy adults.

RETROBULBAR INJECTION: The suggested dose for a 70 kg person is 3-5 mL (120200 mg of Lidocaine HCl (Oracort-E In Orapaste)), ie, 1.7-3 mg/kg or 0.9-1.5 mg/lb body weight. A portion of this is injected retrobulbarly and the rest may be used to block the facial nerve.

TRANSTRACHEAL INJECTION: For local anesthesia by the transtracheal route 2-3 mL should be injected through a large enough needle so that the injection can be made rapidly. By injecting during inspiration some of the drug will be carried into the bronchi and the resulting cough will distribute the rest of the drug over the vocal cords and the epiglottis.

Occasionally it may be necessary to spray the pharynx by oropharyngeal spray to achieve complete analgesia. For the combination of the injection and spray, it should rarely be necessary to utilize more than 5 mL (200 mg of Lidocaine HCl (Oracort-E In Orapaste)), ie, 3 mg/kg or 1.5 mg/lb body weight.

TOPICAL APPLICATION: For laryngoscopy, bronchoscopy and endotracheal intubation, the pharynx may be sprayed with 1-5 mL (40-200 mg of Lidocaine HCl (Oracort-E In Orapaste)), ie, 0.6-3 mg/kg or 0.3-1.5 mg/lb body weight.

Maximum Recommended Dosages

Normal Healthy Adults: The maximum recommended dose of 4% Xylocaine-MPF Sterile Solution should be such that the dose of Lidocaine HCl (Oracort-E In Orapaste) is kept below 300 mg and in any case should not exceed 4.5 mg/kg (2 mg/lb) body weight.

Children

It is difficult to recommend a maximum dose of any drug for children since this varies as a function of age and weight. For children of less than ten years who have a normal lean body mass and normal body development, the maximum dose may be determined by the application of one of the standard pediatric drug formulas (eg, Clark’s rule). For example, in a child of five years weighing 50 lbs., the dose of lidocaine hydrochloride should not exceed 75-100 mg when calculated according to Clark’s rule. In any case, the maximum dose of Xylocaine Solution with epinephrine should not exceed 7 mg/kg (3.2 mg/lb) of body weight. When used without epinephrine, the amount of Xylocaine Solution administered should be such that the dose of lidocaine is kept below 300 mg and in any case should not exceed 4.5 mg/kg (2 mg/lb) of body weight.

NOTE:

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever the solution and container permit. Solutions that are discolored and/or contain particulate matter should not be used.

How supplied

4% Xylocaine-MPF (Lidocaine HCl (Oracort-E In Orapaste)) Sterile Solution, 5 mL ampule.

Store at 20° to 25°C (68° to 77°F).

Manufactured for: APP Pharmaceuticals, LLC, Schaumburg, IL 6017. Revised: February 2010

Adults and Adolescents 12 Years of Age and Older

Children 2 to 12 Years of Age

Administration Information

See also:
What is the most important information I should know about Lidocaine HCl (Oracort-E In Orapaste)?

You should not receive this medication if you are allergic to lidocaine or any other type of numbing medicine.

Before you receive lidocaine injection, tell your doctor if you have liver or kidney disease, heart disease, coronary artery disease, circulation problems, or a history of malignant hyperthermia.

To treat irregular heart rhythms, your doctor may prescribe a LidoPen auto-injector. This is a prefilled automatic injection device to be used in an emergency. Keep the device with you at all times.

Your doctor will describe the signs and symptoms to watch for when deciding when it’s time to use lidocaine injection at home. Never use the LidoPen auto-injector without first calling your doctor.

With the LidoPen auto-injector you will also receive a CardioBeeper to transmit your heart rate and rhythm to your doctor over a telephone. Read all provided instructions and practice using the CardioBeeper.

Lidocaine can cause side effects that may impair your thinking or reactions. Unless absolutely necessary, do not drive after using this medication

See also:
What is the most important information I should know about Triamcinolone acetonide (Oracort-E In Orapaste)?

Use Lidocaine HCl (Oracort-E In Orapaste) as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• Wash your hands well before and after using Lidocaine HCl (Oracort-E In Orapaste).
• Shake well before each use.
• If you are using Lidocaine HCl (Oracort-E In Orapaste) on your face, spray it into your hand. Gently apply. Do not spray Lidocaine HCl (Oracort-E In Orapaste) directly onto your face.
• For other areas, hold the medicine 4 to 6 inches from the skin and spray onto the affected area. Allow the medicine to slowly dry.
• Do not use large amounts of Lidocaine HCl (Oracort-E In Orapaste), especially over blistered or raw areas of your skin.
• Do not bandage or wrap the affected area, unless directed otherwise by your doctor.
• If you miss a dose of Lidocaine HCl (Oracort-E In Orapaste), use it as soon as you remember. Continue to use it as directed by your doctor or on the package label.

Ask your health care provider any questions you may have about how to use Lidocaine HCl (Oracort-E In Orapaste).

Use Triamcinolone acetonide (Oracort-E In Orapaste) as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• Apply Triamcinolone acetonide (Oracort-E In Orapaste) at bedtime unless directed otherwise by your doctor. If you are using Triamcinolone acetonide (Oracort-E In Orapaste) several times per day, apply it after meals unless otherwise directed by your doctor.
• Wash your hands before and after applying Triamcinolone acetonide (Oracort-E In Orapaste).
• Press a small dab (about ¼ inch) to the affected area of the mouth or gums until a thin film develops. A larger amount may be needed to cover some areas. Do not rub in.
• If you miss a dose of Triamcinolone acetonide (Oracort-E In Orapaste), apply it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not apply 2 doses at once.

Ask your health care provider any questions you may have about how to use Triamcinolone acetonide (Oracort-E In Orapaste).

There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.

Lidocaine spray is used to numb the lining of the mouth, throat, or nose before certain medical/dental procedures. It also helps prevent the urge to close the throat (gag reflex), which might make the procedure more difficult. Lidocaine belongs to a class of drugs known as local anesthetics.

How to use Lidocaine HCl (Oracort-E In Orapaste)

Read the Patient Information Leaflet if available from your pharmacist before you start using lidocaine and each time you get a refill. If you have any questions, ask your doctor or pharmacist.

This medication is usually sprayed in the mouth by a health care professional as directed by your doctor right before your procedure.

The dosage is based on your medical condition and response to treatment. In children, the dosage is also based on age and weight.

Numbness may make swallowing difficult and increase your risk of swallowing the wrong way or choking. Do not chew gum or eat for 1 hour after using this product and while your mouth or throat is numb. It is especially important for children to not eat or chew gum for at least 1 hour after their procedures. Be careful not to accidentally bite your tongue or mouth.

Lidocaine starts to numb the affected area within 5 minutes after application. Tell your doctor if the area does not feel numb or the numbness does not go away.

There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.

This medication is used in a variety of conditions such as allergic disorders, arthritis, blood diseases, breathing problems, certain cancers, eye diseases, intestinal disorders, collagen and skin diseases. Talk to your doctor about the risks and benefits of triamcinolone, especially if it is to be injected near your spine (epidural). Rare but serious side effects may occur with epidural use.

Triamcinolone acetonide (Oracort-E In Orapaste) is known as a corticosteroid hormone (glucocorticoid). It works by decreasing your body’s immune response to these diseases and reduces symptoms such as swelling.

How to use Triamcinolone acetonide (Oracort-E In Orapaste) injection

This medication may be given by injecting into different locations such as a muscle (intramuscularly), a skin lesion (intradermally), or a joint (intra-articularly). Injections are usually given by a trained healthcare professional. If you are giving yourself intramuscular injection, you will be taught by your healthcare professional on how to properly use this medication. If any of the information is unclear, consult your healthcare professional.

The injection site, schedule, dosage, and length of treatment are based on your medical condition and response to treatment. Do not inject this medication into a vein (intravenously) or into the spine (epidurally). This medication is not recommended for injection around/into the eye or certain parts of the nose due to the risk for blindness or damage to the eye(s). Consult your doctor for more details.

Use this medication and follow the dosing schedule exactly as directed by your doctor in order to get the most benefit from it. Do not change your dose or use this medication for a longer time than prescribed. Be sure to ask your doctor or pharmacist if you have any questions about your treatment.

Wash hands with soap and water before using this medication. Before using, check this product visually for clumpy particles or discoloration. If either is present, do not use the liquid.

Before injecting each dose intramuscularly, clean the injection site with rubbing alcohol. It is important to change the location of the injection site to avoid discomfort or problem areas. Your dose may need to be gradually decreased to reduce symptoms such as weakness, weight loss, nausea, and extreme fatigue.

Shake vial before use to evenly disperse the suspension. Inject the prescribed dose immediately after withdrawing it into the syringe to avoid settling of the medication in the syringe.

Learn how to store and discard syringes, needles, and medical supplies safely. Consult your pharmacist for more information.

If you have been using this medication for a long time, do not suddenly stop it without your doctor’s approval. Some conditions may become worse when this drug is suddenly stopped.

This medication may be injected into a joint to treat conditions such as arthritis and bursitis. If you have received an injection into a joint, be careful how much stress you put on that joint, even if it is feeling better. Ask your doctor how much you can move the joint while it is healing.

Inform your doctor if your condition worsens or if you have new symptoms.

See also:
What other drugs will affect Lidocaine HCl (Oracort-E In Orapaste)?

Anti-Arrhythmic Drugs: Local anaesthetics of the amide type, such as lignocaine, should be used with caution in patients receiving other local anaesthetics or agents structurally related to amide-type local anaesthetics e.g. certain anti-arrhythmic drugs such as disopyramide, procainamide, mexilitene since potentiation of cardiac effects may occur. Specific interaction studies with lignocaine and anti-arrhythmic drugs class III (eg amiodarone) have not been performed, but caution should be advised.

Amiodarone: Amiodarone has been reported to reduce the clearance of lignocaine in two case reports, although a small prospective study of combined therapy on lignocaine pharmacokinetics found no change in clearance or other pharmacokinetic factor. This combination has been reported to precipitate seizures and to lead to severe sinus bradycardia and a long sinoatrial arrest. Until more experience with concurrent use of lignocaine and amiodarone becomes available, patients receiving the combination should be monitored carefully.

Beta-Adrenoreceptor Antagonists: Propranolol and metoprolol reduce the metabolism of IV administered lignocaine and the possibility of this effect with other beta-adrenergic blockers should be kept in mind. If these drugs are administered concurrently, the patient should be closely observed for signs of lignocaine toxicity.

Cimetidine: Cimetidine reduces the clearance of IV administered lignocaine and toxic effects due to high serum lignocaine levels have been reported when these two drugs have been administered concurrently.

Anticonvulsive Agents: Phenytoin and other antiepileptic drugs such as phenobarbitone, primidone and carbamazepine appear to enhance the metabolism of lignocaine but the significance of this effect is not known. Phenytoin and lignocaine have additive cardiac depressant effects.

Inhalational Anaesthetics: Lignocaine decreases the minimum effective concentration of inhalational anaesthetics such as nitrous oxide.

Skeletal Muscle Relaxants: Lignocaine and skeletal muscle relaxants, e.g. suxamethonium, lead to excessive neuromuscular blockade; therefore this combination must be used with caution.

Structurally Related Local Anaesthetics: Lignocaine should be used with caution in patients receiving agents structurally related to local anaesthetics.

Alkaline Solutions: The solubility of lignocaine is limited at pH values above 7.0. This must be taken into consideration if adding an alkaline solution since precipitation might occur at higher pH values.

Laboratory Test Effects: Creatinine: Creatinine measurements in patients with therapeutic plasma levels of lignocaine are about 15-35% higher when measured by an enzymatic method versus the Jaffe method. This appears to be due to assay interference from N-ethylglycine, a metabolite of lignocaine.

Creatine Kinase: The intramuscular injection of lignocaine may result in an increase in creatine kinase levels for up to 48 hrs. This may interfere with the diagnosis of myocardial infarction.

See also:
What other drugs will affect Triamcinolone acetonide (Oracort-E In Orapaste)?

Aminoglutethimide: Aminoglutethimide may lead to a loss of corticosteroid-induced adrenal suppression.

Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (ie, amphotericin B, diuretics), patients should be observed closely for development of hypokalemia. There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure.

Antibiotics: Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance.

Anticholinesterases: Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy.

Anticoagulants, oral: Coadministration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports. Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect.

Antidiabetics: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required.

Antitubercular drugs: Serum concentrations of isoniazid may be decreased.

Cholestyramine: Cholestyramine may increase the clearance of corticosteroids.

Cyclosporine: Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently. Convulsions have been reported with this concurrent use.

Digitalis glycosides: Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia.

Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect.

Hepatic enzyme inducers (eg, barbiturates, phenytoin, carbamazepine, rifampin): Drugs which induce hepatic microsomal drug metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.

Ketoconazole: Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to an increased risk of corticosteroid side effects.

Nonsteroidal anti-inflammatory drugs (NSAIDs): Concomitant use of aspirin (or other nonsteroidal anti-inflammatory drugs) and corticosteroids increases the risk of gastrointestinal side effects. Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia. The clearance of salicylates may be increased with concurrent use of corticosteroids.

Skin tests: Corticosteroids may suppress reactions to skin tests.

Vaccines: Patients on prolonged corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response. Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines. Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible.

See also:
What are the possible side effects of Lidocaine HCl (Oracort-E In Orapaste)?

Adverse experiences following the administration of lidocaine are similar in nature to those observed with other amide local anesthetic agents. These adverse experiences are, in general, dose-related and may result from high plasma levels caused by excessive dosage, rapid absorption or inadvertent intravascular injection, or may result from a hypersensitivity, idiosyncrasy or diminished tolerance on the part of the patient. Serious adverse experiences are generally systemic in nature. The following types are those most commonly reported:

Central Nervous System

CNS manifestations are excitatory and/or depressant and may be characterized by lightheadedness, nervousness, apprehension, euphoria, confusion, dizziness, drowsiness, tinnitus, blurred or double vision, vomiting, sensations of heat, cold or numbness, twitching, tremors, convulsions, unconsciousness, respiratory depression and arrest. The excitatory manifestations may be very brief or may not occur at all, in which case the first manifestation of toxicity may be drowsiness merging into unconsciousness and respiratory arrest.

Drowsiness following the administration of lidocaine is usually an early sign of a high blood level of the drug and may occur as a consequence of rapid absorption.

Cardiovascular System

Cardiovascular manifestations are usually depressant and are characterized by bradycardia, hypotension, and cardiovascular collapse, which may lead to cardiac arrest.

Allergic

Allergic reactions are characterized by cutaneous lesions, urticaria, edema or anaphylactoid reactions. Allergic reactions as a result of sensitivity to lidocaine are extremely rare and, if they occur, should be managed by conventional means. The detection of sensitivity by skin testing is of doubtful value.

Neurologic

The incidences of adverse reactions associated with the use of local anesthetics may be related to the total dose of local anesthetic administered and are also dependent upon the particular drug used, the route of administration and the physical status of the patient.

There have been reported cases of permanent injury to extraocular muscles requiring surgical repair following retrobulbar administration.

See also:
What are the possible side effects of Triamcinolone acetonide (Oracort-E In Orapaste)?

In adequate, well-controlled and uncontrolled studies, 1187 patients have received Triamcinolone acetonide (Oracort-E In Orapaste) solution. The adverse reactions summarized below, are based upon seven placebo controlled clinical trials of 2-6 weeks duration in 847 patients with seasonal or perennial allergic rhinitis (504 patients received 200 mcg or 400 mcg per day of Triamcinolone acetonide (Oracort-E In Orapaste) solution and 343 patients received vehicle placebo). Adverse events reported by 2% or more of patients (regardless of relationship to treatment) who received Triamcinolone acetonide (Oracort-E In Orapaste) solution 200 or 400 mcg once daily and that were more common with Triamcinolone acetonide (Oracort-E In Orapaste) solution than with placebo are displayed in the table below. Overall, the incidence and nature of adverse events with Triamcinolone acetonide (Oracort-E In Orapaste) solution 400 mcg was comparable to that seen with Triamcinolone acetonide (Oracort-E In Orapaste) solution 200 mcg and with vehicle placebo.

Adverse events reported by 2% or more of patients who received Triamcinolone acetonide (Oracort-E In Orapaste) solution 200 or 400 mcg once daily and that were more common with placebo than with Triamcinolone acetonide (Oracort-E In Orapaste) solution included: application site reaction (e.g. transient nasal burning and stinging), rhinitis, dysmenorrhea, pain (unspecified) and allergic reaction.

The adverse effects related to the irritation of nasal mucous membranes (i.e. application site reaction) did not usually interfere with treatment. In the controlled and uncontrolled studies, approximately 0.3% of patients discontinued because of irritation of nasal mucous membranes.

The active ingredient in XYLOCAINE is lignocaine hydrochloride.

The CAS number for lignocaine hydrochloride (AAN) is 6108-05-0 and lignocaine hydrochloride anhydrous is 73-78-9.

The chemical name for lignocaine hydrochloride is 2-Diethylaminoaceto-2’6′-xylidide.

The Australian Approved Name is lignocaine hydrochloride.

Lignocaine is classed as a membrane stabilising agent and is a local anaesthetic of the amide type. It is extremely stable and plain solutions can be sterilised by autoclaving, repeated a maximum of two times if necessary.

Plain aqueous solutions are sterile, isotonic and contain lignocaine hydrochloride, sodium chloride, sodium hydroxide for pH adjustment and water for injections. XYLOCAINE solutions contain no antimicrobial agent and should be used only once and any residue discarded.

Plain aqueous solutions of lignocaine hydrochloride have a pH of 5.0-7.0 (approx.). Lignocaine base has a pKa of 7.85 (25°C), an oil/water coefficient of 2.9 and a molecular weight of 234.3.

Each actuation delivers Triamcinolone acetonide (Oracort-E In Orapaste) 55 mcg from the nasal actuator after an initial priming of 5 sprays. It will remain adequately primed for 2 weeks. If Triamcinolone acetonide (Oracort-E In Orapaste) is not used for >2 weeks, then it can be adequately reprimed with 1 spray. The contents of one 6.5-g bottle provide 30 actuations, and the contents of one 16.5-g bottle provide 120 actuations. After either 30 or 120 actuations, the amount of Triamcinolone acetonide (Oracort-E In Orapaste) delivered per actuation may not be consistent and the unit should be discarded. Each 30- and 120-actuation bottle contains Triamcinolone acetonide (Oracort-E In Orapaste) 3.575 and 9.075 mg, respectively.

Triamcinolone acetonide (Oracort-E In Orapaste) also contains the following excipients: Microcrystalline cellulose, carboxymethylcellulose sodium, polysorbate 80, dextrose, benzalkonium chloride and disodium edetate; hydrochloric acid or sodium hydroxide may be added to adjust the pH to a target of 5 within a range of 4.5 and 6.

Triamcinolone acetonide (Oracort-E In Orapaste) is an unscented, thixotropic, water-based metered-dose pump spray formulation unit containing a microcrystalline suspension of Triamcinolone acetonide (Oracort-E In Orapaste) in an aqueous medium.

Triamcinolone acetonide (Oracort-E In Orapaste) is a nonchlorofluorocarbon (non-CFC)-containing metered-dose pump spray.

Triamcinolone acetonide (Oracort-E In Orapaste) is 9-fluoro-11β,16α,17, 21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with acetone (C₂₄H₃₁FO₆). It has a molecular weight of 434.51.